Obesity is silently crippling New Zealand's health system, and one controversial drug might hold the key to turning the tide. But here's where it gets controversial: should taxpayers foot the bill for weight loss medications like Wegovy? This question is currently at the heart of a heated debate, as Pharmac seeks clinical advice on whether to fund this groundbreaking treatment. With New Zealand boasting the third-highest adult obesity rate in the OECD, the stakes couldn’t be higher. One in three adults and one in eight children are classified as obese, a statistic that’s hard to ignore.
Pharmac has received two applications to fund Wegovy (semaglutide), a GLP-1 receptor agonist designed for weight loss. The first application, submitted in September, targets individuals with established cardiovascular disease and a Body Mass Index (BMI) of 27 or higher. The second, filed in October, focuses on chronic weight management for those with a BMI of 30 or higher and at least one weight-related comorbidity. Pharmac’s director of advice and assessment, David Hughes, assures that expert guidance will be published later this month. And this is the part most people miss: the assessment will not only evaluate the drug’s effectiveness compared to current funded options but also its broader impact on individuals, families, caregivers, and the entire health system.
Hughes also revealed that Pharmac is reviewing an application to fund Saxenda (liraglutide) for individuals with very high BMIs. Meanwhile, Australia has already taken the plunge, announcing on Monday that Wegovy will be subsidised for patients with cardiovascular disease and a BMI of 35 or higher. This move slashes the cost to AU$25 (NZ$29) per prescription, or AU$7.70 (NZ$9) for concession card holders—a stark contrast to New Zealand’s current price tag of $459.99 per month.
Associate Minister of Health David Seymour stops short of dictating Pharmac’s decisions but urges them to rethink their budget strategies. “Funding new drugs like Wegovy could save taxpayers money in the long run by reducing costs associated with obesity-related diseases,” he argues. Weight loss specialist Dr. Gerard McQuinlan echoes this sentiment, pointing out that obesity is linked to over 200 diseases, including Type 2 diabetes, which costs the health system $2.1 billion annually. “By addressing obesity, we could significantly cut these expenses,” he explains.
But the debate doesn’t end there. Here’s the bold question: Is funding Wegovy a sustainable solution, or could it lead to dependency on medication? Dr. McQuinlan dismisses concerns about shortages, especially once the pill form becomes available in New Zealand. However, he stresses that obesity is a chronic, relapsing disease, with a 95% chance of weight regain without ongoing management. “It’s not about willpower—it’s a hormonal issue,” he clarifies. Wegovy works by targeting the hormone that controls satiety, helping individuals feel full and break the cycle of overeating.
As Pharmac weighs its options, the public is left to ponder: Is this the game-changer New Zealand’s health system needs, or is it a costly Band-Aid? We want to hear from you. Do you think funding Wegovy is a wise investment, or are there better ways to tackle the obesity crisis? Share your thoughts in the comments below and join the conversation.
Don’t miss out on the latest updates—sign up for Ngā Pitopito Kōrero, our daily newsletter curated by expert editors, delivered straight to your inbox every weekday. Subscribe here.
